Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3

çabalak, mehmet; Bal, Tayibe

doi:10.5455/annalsmedres.2020.04.413

Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3

Tayibe BAL, (Hatay Mustafa Kemal Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Hatay, Türkiye)

Mehmet ÇABALAK (Hatay Mustafa Kemal Üniversitesi, Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Hatay, Türkiye)

Annals of Medical Research

1 1

Yıl: 2020 Cilt: 27 Sayı: 8 Sayfa Aralığı: 2067 - 2071 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2020.04.413 İndeks Tarihi: 06-12-2020

Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3

Öz:

Aim: Few studies have evaluated real-world clinical experience with sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV)genotypes 2 and 3 infections from Turkey. Thus, this study aimed to investigate the results of sofosbuvir plus ribavirin therapy ingenotype 2 and 3 cases followed in an infectious disease clinic at a university hospital in Hatay, southern Turkey.Material and Methods: In this single-centre, retrospective, observational study, 58 eligible patients treated with SOF/RBV (400 mgof SOF plus weight-based RBV) therapy between October 2016 and February 2019 were examined. Forty-three patients who hadcompleted the duration of treatment and had known virological response status were evaluated for treatment outcomes.Results: SOF/RBV achieves a sustained virological response (SVR) rate of 96.3% and 100% in the HCV genotype 2 and 3 groups,respectively, with treatment duration of 12-24 weeks. No patient experienced a virologic breakthrough while only one experiencedvirologic relapse after the completion of therapy. The incidence of adverse events was 25.5% (11/43) while the most common(11.6%) adverse event was ribavirin-related hemolytic anemia.Conclusion: The current study revealed that the SOF/RBV therapy achieved excellent response rates with a good safety profile innon-cirrhotic Turkish patients infected with HCV genotype 2 or 3.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. World Health Organization. WHO model list of essential medicines. Retrieved February 12, 2020, from https://www.who.int/medicines/publications/ essentialmedicines/en/
2. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61:45-57.
3. Çetin Duran A, Kaya Çetinkaya Ö, Sayıner AA, et al. Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data. Turk J Gastroenterol 2020;31:128-35.
4. Robaeys G, Bielen R, Azar DG, et al. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol 2016;65:1094-103.
5. Edlin BR, Carden MR. Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis 2006;42:673-6.
6. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
7. Welzel TM, Nelson DR, Morelli G, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 2017;66:1844-52.
8. Tsai WL, Wang CF, Cheng JS, et al. Sofosbuvirbased r egimen for genotype 2 HCV infected patients in Taiwan: A real World experience. PLoS One 2020;15:e0227424.
9. Kurtaran B, Sarıgül F, Çabalak M, et al. Efficacy and safety of direct-acting antivirals in chronic hepatitis C patients infected with genotype 2 and 3 in Turkey. AASLD-TASL Connect Regional Meeting, 15-16 March, 2019. İstanbul, Turkey, 59-60.
10. Örmeci N, Gülşen MT, Sezgin O, et al. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turk J Gastroenterol. 2020;31:148-55.
11. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014;21:762-8.
12. Wehmeyer MH, Ingiliz P, Christensen S, et al. Realworld effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03). J Med Virol 2018;90:304-12.
13. Huang R, Rao H, Xie Q, et al. Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. J Med Virol 2019;91:1313-8.
14. Su F, Green PK, Berry K, et al. The association between race/ethnicity and the effectiveness of direct acting antiviral agents for hepatitis C virus infection. Hepatology 2016;65:426-38.
15. Lu M, Wu KH, Li J, et al. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. J Viral Hepat 2019;26:1210-7.
16. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Eng J Med 2013;368:34-44.
17. Chen CH, Yu ML. Evolution of interferon-based therapy for chronic Hepatitis C. Hepat Res Treat 2010;2010:140953.
18. Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferonalfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015;149:1462-70.
19. Kattakuzhy S, Levy R, Rosenthal E, et al. Hepatitis C genotype 3 disease. Hepatol Int 2016;10:861-70.
20. Chan A. Genotype 3 Infection-The last stand of hepatitis C virus. Drugs 2017;77:131-44.
21. Cho Y, Cho EJ, Lee JH, et al. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Clin Mol Hepatol 2015;21:358-64.
22. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
23. Sulkowski MS, Cooper C, Hunyady B, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011;8:212-3.
24. Ahn SH, Lim YS, Lee KS, et al. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. J Viral Hepat 2016;23:358-65.
25. Cornberg M, Petersen J, Schober A, et al. Real-world use, effectiveness and safety of antiviral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther 2017;45:688-700.
26. Atsukawa M, Tsubota A, Kondo C, et al. Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Dig Liver Dis 2017;49:1029-35.
27. Kao JH, Chien RN, Chang TT, et al. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int 2016;36:1101-7.
28. Chen CC, Tung SY, Wei KL, et al. Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin. J Formos Med Assoc 2020;119:532-7.

APA	Bal T, çabalak m (2020). Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. , 2067 - 2071. 10.5455/annalsmedres.2020.04.413
Chicago	Bal Tayibe,çabalak mehmet Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. (2020): 2067 - 2071. 10.5455/annalsmedres.2020.04.413
MLA	Bal Tayibe,çabalak mehmet Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. , 2020, ss.2067 - 2071. 10.5455/annalsmedres.2020.04.413
AMA	Bal T,çabalak m Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. . 2020; 2067 - 2071. 10.5455/annalsmedres.2020.04.413
Vancouver	Bal T,çabalak m Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. . 2020; 2067 - 2071. 10.5455/annalsmedres.2020.04.413
IEEE	Bal T,çabalak m "Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3." , ss.2067 - 2071, 2020. 10.5455/annalsmedres.2020.04.413
ISNAD	Bal, Tayibe - çabalak, mehmet. "Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3". (2020), 2067-2071. https://doi.org/10.5455/annalsmedres.2020.04.413

APA	Bal T, çabalak m (2020). Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. Annals of Medical Research, 27(8), 2067 - 2071. 10.5455/annalsmedres.2020.04.413
Chicago	Bal Tayibe,çabalak mehmet Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. Annals of Medical Research 27, no.8 (2020): 2067 - 2071. 10.5455/annalsmedres.2020.04.413
MLA	Bal Tayibe,çabalak mehmet Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. Annals of Medical Research, vol.27, no.8, 2020, ss.2067 - 2071. 10.5455/annalsmedres.2020.04.413
AMA	Bal T,çabalak m Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. Annals of Medical Research. 2020; 27(8): 2067 - 2071. 10.5455/annalsmedres.2020.04.413
Vancouver	Bal T,çabalak m Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3. Annals of Medical Research. 2020; 27(8): 2067 - 2071. 10.5455/annalsmedres.2020.04.413
IEEE	Bal T,çabalak m "Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3." Annals of Medical Research, 27, ss.2067 - 2071, 2020. 10.5455/annalsmedres.2020.04.413
ISNAD	Bal, Tayibe - çabalak, mehmet. "Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3". Annals of Medical Research 27/8 (2020), 2067-2071. https://doi.org/10.5455/annalsmedres.2020.04.413